MarketCapExport financials
Avanos Medical (AVNS)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Avanos Medical Income Statement 2025-2011 | AVNS
Brief overview of financial results at Avanos Medical
The comparison covers a five-year financial horizon. According to figures from Avanos Medical, revenue changed from 715 million dollars to 701 million dollars over five years. The total change was −1.9%, with a CAGR of approximately −0.4%. The business did not achieve meaningful top-line expansion.
The gross result shifted from $371 million to $354 million, or −4.6%. There was no major divergence between sales and cost of revenue. Gross margin moved from 51.9% to 50.5%. There was no meaningful shift in gross profitability.
EBITDA was −5.6 million dollars at the beginning and −22.7 million dollars at the end of the period (−305.4%). EBITDA lagged revenue, showing weaker operating momentum. EBITDA margin moved from −0.8% to −3.2%. Operating return per unit of revenue declined.
Across the five years, the net result shifted from −$29 million to −$72.9 million. Profitability deteriorated further over the five years.
The market value of the business moved from $2.2 billion to $628 million, or −71.4%. Investors responded cautiously to the improvement in the business.
Summary assessment
The financial trajectory is weak and requires a cautious interpretation. The weaker side of the profile includes pressure from direct costs, a narrow EBITDA buffer and declining net profitability. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Avanos Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
628 M | 721 M | 731 M | 1.36 B | 1.67 B | 2.19 B | 1.34 B | 2.14 B | 2.3 B | 1.77 B | 1.16 B | 2.07 B | - | - | - |
Shares |
46.3 M | 46 M | 46.6 M | 46.9 M | 48.1 M | 47.8 M | 47.6 M | 47.2 M | 46.8 M | 46.6 M | 46.6 M | 46.5 M | - | - | - |
Historical Prices |
13.6 | 15.7 | 15.7 | 29 | 34.7 | 45.9 | 33.7 | 44.8 | 46.2 | 37 | 33.4 | 45.5 | - | - | - |
Net Income |
-72.9 M | -392 M | -61.8 M | 50.5 M | 6.3 M | -29 M | -45.9 M | 57.5 M | 79.3 M | 39.8 M | -426 M | 27.1 M | 155 M | 153 M | 142 M |
Revenue |
701 M | 688 M | 673 M | 684 M | 587 M | 715 M | 698 M | 652 M | 612 M | 1.59 B | 1.57 B | 1.67 B | 1.68 B | 1.68 B | 1.66 B |
Cost of Revenue |
347 M | 306 M | 294 M | 290 M | 288 M | 344 M | 295 M | 261 M | 275 M | 269 M | - | - | - | - | - |
Gross Profit |
354 M | 381 M | 380 M | 394 M | 299 M | 371 M | 402 M | 391 M | 337 M | 558 M | 532 M | 549 M | 612 M | 602 M | 591 M |
Operating Income |
-61.6 M | -396 M | 4.2 M | 35.5 M | -39 M | -48.5 M | -55.7 M | 500 K | -43.1 M | -107 M | -136 M | 94.3 M | 225 M | 228 M | - |
Interest Expense |
- | - | - | - | 3.3 M | 15.6 M | 15 M | 26.4 M | 31.6 M | 32.7 M | 33.1 M | 6 M | 100 K | 800 K | - |
EBITDA |
-22.7 M | -351 M | 50.3 M | 83.2 M | -700 K | -5.6 M | -18.8 M | 34 M | 16.4 M | 153 M | 162 M | 180 M | 294 M | 286 M | 262 M |
Operating Expenses |
416 M | 778 M | 376 M | 359 M | 338 M | 419 M | 458 M | 390 M | 380 M | 470 M | 435 M | 454 M | 387 M | 374 M | 380 M |
General and Administrative Expenses |
316 M | 318 M | 335 M | 326 M | 285 M | 333 M | 399 M | 340 M | 322 M | 411 M | 398 M | 424 M | 351 M | 343 M | 352 M |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Avanos Medical
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
46.5 M | 46.5 M | 46.4 M | 46.3 M | 46.1 M | 46 M | 46 M | 45.9 M | 46.2 M | -100 K | 46.8 M | 46.8 M | 46.6 M | -200 K | 46.6 M | 47.2 M | 47.4 M | 48.2 M | 48.1 M | 48.1 M | 48 M | 47.9 M | 47.8 M | 47.8 M | 47.8 M | 47.7 M | 47.7 M | 47.6 M | 47.5 M | 100 K | 47.3 M | 47.1 M | 46.9 M | 100 K | 46.8 M | 46.7 M | 46.7 M | 46.7 M | 46.7 M | 46.7 M | 46.7 M | 46.6 M | 46.6 M | 46.6 M | 46.5 M | 46.5 M | 46.5 M | 46.5 M | 46.5 M | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
5.1 M | -1.3 M | -1.4 M | -76.8 M | 6.6 M | - | 4.3 M | 1.8 M | -900 K | 10.5 M | -3.7 M | -68.1 M | -500 K | 16.9 M | 15.7 M | 12.5 M | 5.4 M | 11.5 M | -35.3 M | 38.5 M | -8.4 M | -49 M | 19.3 M | -3 M | 3.7 M | -6.1 M | -11.5 M | -8 M | -20.3 M | -2.2 M | 4.2 M | 35.3 M | 20.2 M | 32.8 M | 16.6 M | 17.1 M | 12.8 M | 10 M | 9.1 M | 6.5 M | 12.8 M | 14.5 M | -470 M | 8 M | 21.7 M | -2.4 M | -7.4 M | -4.5 M | 41.4 M | - | 47.9 M | - | - | - | - | - | - | - | - | - | - |
Revenue |
182 M | 181 M | 178 M | 175 M | 168 M | - | 170 M | 172 M | 166 M | 173 M | 171 M | 169 M | 159 M | 182 M | 172 M | 171 M | 197 M | 35.8 M | 184 M | 186 M | 181 M | 185 M | 186 M | 164 M | 180 M | 190 M | 171 M | 172 M | 164 M | 170 M | 165 M | 161 M | 156 M | 166 M | 150 M | 149 M | 146 M | - | 398 M | 400 M | 146 M | - | 390 M | 389 M | 394 M | - | 408 M | 414 M | 411 M | - | 420 M | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
88 M | 94.9 M | 91.8 M | 82.9 M | 77.7 M | - | 77.5 M | 76.1 M | 71.3 M | 78.3 M | 75.8 M | 71.6 M | 67.9 M | 78.7 M | 72.1 M | 69.3 M | 90.8 M | 3.5 M | 93.9 M | 100 M | 90.4 M | 98.5 M | 89.9 M | 77.2 M | 78.3 M | 80.1 M | 76.4 M | 73.5 M | 65.4 M | 69.5 M | 60.4 M | 66.2 M | 65.3 M | 76.4 M | 69.5 M | 64.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
94.2 M | 86 M | 86 M | 92.1 M | 89.8 M | - | 92.9 M | 95.6 M | 94.8 M | 95 M | 95.5 M | 97.8 M | 91.4 M | 103 M | 100 M | 102 M | 107 M | 32.3 M | 90.2 M | 85.7 M | 91.3 M | 86.5 M | 95.8 M | 86.5 M | 102 M | 110 M | 95 M | 98.7 M | 98.8 M | 100 M | 105 M | 94.7 M | 91.1 M | 89.9 M | 81 M | 84.5 M | 81.5 M | -118 M | 138 M | 141 M | 81.5 M | -140 M | 131 M | 135 M | 132 M | 156 M | 132 M | 105 M | 155 M | - | 162 M | - | - | - | - | - | - | - | - | - | - |
Operating Income |
8.9 M | 2.5 M | 100 K | -74.5 M | 10.3 M | - | 12 M | 6.3 M | 4 M | 11.2 M | 1.2 M | -2.1 M | -6.1 M | 16.6 M | 12.8 M | 10.1 M | 8.6 M | -22.4 M | 3.4 M | -7.3 M | -12.4 M | -47.2 M | -100 K | -1.8 M | 600 K | -3.2 M | -18.1 M | -9.8 M | -24.6 M | -8.3 M | 7 M | 8.8 M | -7 M | -3 M | -10.4 M | -12.1 M | -17.6 M | -179 M | 20.9 M | 17.6 M | -17.6 M | 262 M | -461 M | 22.1 M | 40.9 M | 24 M | 13.1 M | -4.5 M | 61.7 M | - | 70.3 M | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
- | - | - | - | - | - | - | - | 3.1 M | 3.3 M | 4.7 M | 3.5 M | 3.5 M | 3 M | 3 M | 2.7 M | 1.3 M | 700 K | 900 K | 900 K | 800 K | 2.7 M | 4.3 M | 4.3 M | 4.3 M | 4.3 M | 3.5 M | 3.5 M | 3.7 M | 3.5 M | 4.2 M | 9.9 M | 8.8 M | 8.1 M | 8.1 M | 7.8 M | 7.6 M | 8 M | 8.4 M | 8.3 M | 7.6 M | 8.1 M | 7.8 M | 8.9 M | 8.3 M | 5.9 M | 100 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
14.5 M | -100 M | 5.1 M | -69.7 M | 118 M | - | 18.4 M | 12.6 M | 10.1 M | 17.7 M | 7.4 M | 3.7 M | -300 K | 23.8 M | 18.3 M | 15.8 M | 14.3 M | -20.3 M | 7.6 M | -3.2 M | -8.2 M | -42.4 M | 4.8 M | 3.1 M | 5.4 M | 2 M | -12.9 M | -5 M | -19.8 M | -2.9 M | 12.4 M | 13.5 M | -2.5 M | 2.2 M | -5.3 M | -7 M | -1.4 M | -173 M | 26.9 M | 22.6 M | -12.3 M | 268 M | -455 M | 28.1 M | 46.9 M | 32 M | 21.1 M | 30.3 M | 79 M | - | 123 M | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
85.3 M | 83.5 M | 85.9 M | 167 M | 79.5 M | - | 80.9 M | 89.3 M | 90.8 M | 83.8 M | 94.3 M | 99.9 M | 97.5 M | 86.3 M | 87.4 M | 91.5 M | 98 M | 54.7 M | 86.8 M | 93 M | 104 M | 134 M | 95.9 M | 88.3 M | 102 M | 113 M | 113 M | 108 M | 123 M | 109 M | 97.7 M | 85.9 M | 98.1 M | 92.9 M | 91.4 M | 96.6 M | - | 60.7 M | 117 M | 123 M | 99.1 M | -403 M | 592 M | 113 M | 91.2 M | 132 M | 119 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
77.7 M | 78.8 M | 77.6 M | 83.5 M | 75.7 M | - | 74.3 M | 80.9 M | 83.6 M | 74.5 M | 78.7 M | 93 M | 88.8 M | 78.7 M | 78.3 M | 83.2 M | 90.1 M | 60.2 M | 75 M | 76.7 M | 73.4 M | 82.2 M | 82.4 M | 76.9 M | 91.1 M | 104 M | 94.4 M | 94.7 M | 106 M | 87.9 M | 86.3 M | 79.8 M | 86.4 M | 77.4 M | 78.4 M | 81.1 M | 84.8 M | 45.2 M | 100 M | 108 M | 84.8 M | 49.5 M | 97.2 M | 106 M | 97.2 M | 126 M | 111 M | 101 M | 85.5 M | - | 82.5 M | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Avanos Medical (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Abbott Laboratories
ABT
|
$ 110.59 | 0.07 % | $ 193 B |  USA |
 |
EDAP TMS S.A.
EDAP
|
- | - | $ 162 M |  France |
 |
Align Technology
ALGN
|
$ 174.54 | 0.16 % | $ 12.7 B | USA |
 |
TELA Bio
TELA
|
$ 0.83 | -4.37 % | $ 39 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
$ 104.0 | -0.68 % | $ 60.8 B | USA |
 |
Avinger
AVGR
|
- | -20.74 % | $ 369 K | USA |
 |
CONMED Corporation
CNMD
|
$ 51.21 | -1.42 % | $ 1.59 B | USA |
 |
Medtronic PLC
MDT
|
$ 101.59 | -1.17 % | $ 130 B | USA |
 |
MiMedx Group
MDXG
|
$ 3.37 | 1.36 % | $ 498 M | USA |
 |
ThermoGenesis Holdings
THMO
|
- | -25.84 % | $ 171 K | USA |
 |
Talis Biomedical Corporation
TLIS
|
- | 3.55 % | $ 7.96 M | USA |
 |
Myomo
MYO
|
$ 1.32 | -5.71 % | $ 55.2 M | USA |
 |
Insulet Corporation
PODD
|
$ 148.03 | -1.19 % | $ 10.4 B | USA |
 |
Profound Medical Corp.
PROF
|
$ 7.66 | 4.36 % | $ 232 M |  Canada |
 |
Quanterix Corporation
QTRX
|
$ 3.3 | -2.51 % | $ 141 M | USA |
 |
Viveve Medical
VIVE
|
- | -15.35 % | $ 1.71 M | USA |
 |
Smith & Nephew plc
SNN
|
$ 30.96 | -0.29 % | $ 26.8 B |  Britain |
 |
Sensus Healthcare
SRTS
|
$ 3.42 | 7.39 % | $ 55.8 M | USA |
 |
Stryker Corporation
SYK
|
$ 324.18 | -0.48 % | $ 124 B | USA |
 |
Tactile Systems Technology
TCMD
|
$ 26.61 | 0.08 % | $ 609 M | USA |
 |
TransMedics Group
TMDX
|
$ 91.02 | -2.95 % | $ 3.09 B | USA |
 |
SmileDirectClub
SDC
|
- | -53.45 % | $ 9.71 M | USA |
 |
Viemed Healthcare
VMD
|
$ 9.04 | 1.01 % | $ 352 M | USA |
 |
Varex Imaging Corporation
VREX
|
$ 18.45 | 0.03 % | $ 764 M | USA |
 |
Acutus Medical
AFIB
|
- | -26.83 % | $ 2.62 M | USA |
 |
Vivos Therapeutics
VVOS
|
$ 0.09 | -8.14 % | $ 925 K | USA |
 |
BIOLASE
BIOL
|
- | -13.19 % | $ 166 K | USA |
 |
SeaSpine Holdings Corporation
SPNE
|
- | 0.28 % | $ 270 M | USA |
 |
Xtant Medical Holdings
XTNT
|
$ 0.28 | -0.68 % | $ 39.1 M | USA |
 |
Zimmer Biomet Holdings
ZBH
|
$ 107.39 | -0.87 % | $ 21.3 B | USA |
 |
Apollo Endosurgery
APEN
|
- | - | $ 475 M | USA |
 |
NuVasive
NUVA
|
- | - | $ 2.07 B | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
$ 0.37 | 59.63 % | $ 24 M |  Israel |
 |
Penumbra
PEN
|
$ 321.48 | -0.11 % | $ 12.5 B | USA |
 |
Conformis
CFMS
|
- | - | $ 16.4 M | USA |
 |
ViewRay
VRAY
|
- | 1.54 % | $ 468 M | USA |
 |
Medigus Ltd.
MDGS
|
- | 10.28 % | $ 55.5 M | Israel |
 |
Boston Scientific Corporation
BSX
|
$ 44.68 | 1.49 % | $ 66.1 B | USA |
 |
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | USA |
 |
Neovasc
NVCN
|
- | - | $ 111 M | Canada |
 |
Vapotherm
VAPO
|
- | 6.72 % | $ 34 M | USA |
 |
Nevro Corp.
NVRO
|
- | - | $ 217 M | USA |
 |
Venus Concept
VERO
|
- | - | $ 726 K | USA |
 |
Eargo
EAR
|
- | - | $ 10.2 M | USA |
 |
Sientra
SIEN
|
- | -16.59 % | $ 10.3 M | USA |
 |
Silk Road Medical, Inc
SILK
|
- | - | $ 1.07 B | USA |
 |
Surgalign Holdings
SRGA
|
- | -32.98 % | $ 1.68 M | USA |
 |
Cardiovascular Systems
CSII
|
- | 0.15 % | $ 844 M | USA |
 |
ShockWave Medical
SWAV
|
- | - | $ 12.3 B | USA |
 |
Inari Medical
NARI
|
- | - | $ 4.23 B | USA |